Patent number: 8399412
Abstract: A method of treatment for treating, at least partly preventing, inhibiting or reducing tissue deterioration, injury or damage due to a periodontal disease or disease of oral mucosa, or for restoring tissue adversely affected by the disease, in a subject, and/or for downregulating NF-kappaB or suppressing NF-kappaB mediated action in a body, organ, tissue or cell, includes administering to a subject, body, organ, tissue or cell an effective amount of a composition including a peptide agent including at least one of Thymosin beta 4 (T?4), an isoform of T?4, an N-terminal fragment of T?4, a C-terminal fragment of T?4, T?4 sulfoxide, an LKKTET peptide or conservative variant thereof, an LKKTNT peptide or conservative variant thereof, a KLKKTET peptide or conservative variant thereof, an LKKTETQ peptide or conservative variant thereof, T?4ala, T?9, T?10, T?11, T?12, T?13, T?14, T?15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, DnaseI, vilin, fragmin, severin, capping protein, ?-actinin,
Type:
Grant
Filed:
October 5, 2007
Date of Patent:
March 19, 2013
Assignee:
RegeneRx Biopharmaceuticals, Inc.
Inventors:
Gabriel Sosne, Michelle Wheater, Allan L. Goldstein